Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis
NCT05251870Phase 2Unknown
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of TolDCB29 in rheumatoid arthritis (RA) (4 arms). Primary endpoints: Occurrence and severity of adverse events at 34 weeks, Quantity of good manufacturing practices (GMP)-grade TolDCB29 released at 34 weeks and 1 more. Status: unknown.
02
Drugs
TolDCB29
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05251870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251870.